Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus

Abstract Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10–15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcomes. The NAXIVA trial demonstrated a 35% VTT response...

詳細記述

書誌詳細

出版年:	Nature Communications
主要な著者:	Rebecca Wray, Hania Paverd, Ines Machado, Johanna Barbieri, Farhana Easita, Abigail R. Edwards, Ferdia A. Gallagher, Iosif A. Mendichovszky, Thomas J. Mitchell, Maike de la Roche, Jacqueline D. Shields, Stephan Ursprung, Lauren Wallis, Anne Y. Warren, Sarah J. Welsh, Mireia Crispin-Ortuzar, Grant D. Stewart, James O. Jones, On behalf of the NAXIVA Study Group
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2025-04-01
オンライン･アクセス:	https://doi.org/10.1038/s41467-025-58436-8